Ayala Pharmaceuticals (NASDAQ:ADXS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report released on Sunday morning. The firm issued a sell rating on the stock.

Ayala Pharmaceuticals Price Performance

NASDAQ ADXS opened at $0.03 on Friday. The stock has a market cap of $1.15 million, a PE ratio of 0.00 and a beta of 1.62. The business has a 50 day moving average price of $0.03 and a two-hundred day moving average price of $0.06. Ayala Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $1.49.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.